Drug Innovation
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Drug Innovation
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Commentary
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
Commentary
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
Commentary
A lawsuit that may kill tomorrow’s cures
On Wednesday, May 6, the California Supreme Court will hear a case that could upend the economics of medical innovation. Roughly 24,000 plaintiffs are suing pharmaceutical company Gilead over one of its HIV drugs. They do not claim that the drug failed to work, nor that it was defectively manufactured, ...
Commentary
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
Commentary
Price Controls Could Prevent the Next ‘Miracle Drug’
The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer’s, chronic respiratory diseases, and stroke have all declined in recent years, too. These gains didn’t happen by accident. They’re the result of ...
Commentary
Don’t undermine the system that incentivized GLP-1 development
A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications. Rescinding the patents is a dangerous idea that ...
Commentary
The Legislature shouldn’t decide what vaccines to make illegal
A bill currently making its way through the Idaho Legislature could put the health of countless people at risk. Idaho’s Senate Health Committee recently atdvanced legislation that would impose a two-year moratorium on certain human gene therapy products and ban the use of mRNA vaccines for children and pregnant women ...
Commentary
An anti-science FDA is a threat to our health and prosperity
The U.S. Food and Drug Administration supposedly “implements gold standard science.” Yet the agency appears to relish obstructing scientific progress. Earlier this month, Vinay Prasad, the director of FDA’s vaccine division, rejected Moderna’s application for a new mRNA flu vaccine for adults 50 and older on dubious grounds. The FDA ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
A lawsuit that may kill tomorrow’s cures
On Wednesday, May 6, the California Supreme Court will hear a case that could upend the economics of medical innovation. Roughly 24,000 plaintiffs are suing pharmaceutical company Gilead over one of its HIV drugs. They do not claim that the drug failed to work, nor that it was defectively manufactured, ...
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
Price Controls Could Prevent the Next ‘Miracle Drug’
The death rate from cancer in the United States has fallen by more than one-third since 1991. HIV-related mortality has dropped ninefold since 1995. Death rates for Alzheimer’s, chronic respiratory diseases, and stroke have all declined in recent years, too. These gains didn’t happen by accident. They’re the result of ...
Don’t undermine the system that incentivized GLP-1 development
A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications. Rescinding the patents is a dangerous idea that ...
The Legislature shouldn’t decide what vaccines to make illegal
A bill currently making its way through the Idaho Legislature could put the health of countless people at risk. Idaho’s Senate Health Committee recently atdvanced legislation that would impose a two-year moratorium on certain human gene therapy products and ban the use of mRNA vaccines for children and pregnant women ...
An anti-science FDA is a threat to our health and prosperity
The U.S. Food and Drug Administration supposedly “implements gold standard science.” Yet the agency appears to relish obstructing scientific progress. Earlier this month, Vinay Prasad, the director of FDA’s vaccine division, rejected Moderna’s application for a new mRNA flu vaccine for adults 50 and older on dubious grounds. The FDA ...